A
Alcista
Alcista · 25%VXRT
$1.66
Precio del escenario
$0.320
-0.080 (-25.06%)Al cierre
Loading chart…
- Máximo
- 0.430
- Apertura
- 0.412
- Precio medio ponderado por volumen
- 0.35
- Volumen
- 24.02M
- Capitalización
- 118.17M
- Mínimo
- 0.300
- Importe
- 8.41M
- EV/EBITDA, TTM
- -7.36
Vaxart, Inc. is a clinical-stage biotechnology company that is primarily focused on the development of oral recombinant vaccines based on its Vector-Adjuvant-Antigen Standardized Technology (VAAST) proprietary oral vaccine platform. Its vaccines are designed to be administered using pills that can be stored and shipped without refrigeration and eliminate the risk of needle-stick injury. The Company’s development programs include pill vaccines designed to protect against coronavirus, norovirus and influenza, as well as a therapeutic vaccine for human papillomavirus (HPV), its first immune-oncology indication. The Company's platform technology employs a vector-based approach and consists of various components, such as vector, antigen, and adjuvant. A vector is a virus used as a carrier to deliver DNA coding for vaccine antigens and an adjuvant selected to activate the immune system. An antigen is a viral or bacterial protein that stimulates an immune response to the targeted pathogen.
Métricas de valoración
El PER previsto actual de Vaxart Inc (VXRT) es -1.49, frente a su media de 5 años de -2.66.
Escenarios de precio de Alphio AI para VXRT
Los precios por escenario son la última banda de previsión mensual del año en curso. Las probabilidades son pesos fijos del modelo (25 / 50 / 25), no garantías.
Cronología de eventos
Noticias
9.007-17NewsfilterVaxart Annual Meeting Results Show Key Approvals
8.506-26NewsfilterVaxart Board's Strategic Actions to Drive Value Creation
- 9.505-09seekingalpha
Vaxart Reports Q1 2026 Earnings with Strategic Updates
- 9.505-01Newsfilter
Vaxart to Report Q1 2026 Financial Results on May 7
- 5.004-23Newsfilter
Vaxart Appoints New Board Member to Enhance Vaccine Development Expertise
Preguntas frecuentes sobre VXRT, respondidas por Alphio AI
Vaxart, Inc. is a clinical-stage biotechnology company that is primarily focused on the development of oral recombinant vaccines based on its Vector-Adjuvant-Antigen Standardized Technology (VAAST) proprietary oral vaccine platform. Its vaccines are designed to be administered using pills that can be stored and shipped without refrigeration and eliminate the risk of needle-stick injury. The Company’s development programs include pill vaccines designed to protect against coronavirus, norovirus and influenza, as well as a therapeutic vaccine for human papillomavirus (HPV), its first immune-oncology indication. The Company's platform technology employs a vector-based approach and consists of various components, such as vector, antigen, and adjuvant. A vector is a virus used as a carrier to deliver DNA coding for vaccine antigens and an adjuvant selected to activate the immune system. An antigen is a viral or bacterial protein that stimulates an immune response to the targeted pathogen. It operates in the Healthcare sector (BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) industry).
Comunidad
Más ↗Aún no hay publicaciones
Regístrate o inicia sesión para participarEsta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.